November 27, 2019
Ver artículo completoPredictors of Primary Response to Biologic Treatment Anti-TNF, Vedolizumab, and Ustekinumab in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
In summary, currently no single marker fulfils all criteria for being an appropriate prognostic indicator of response to any biologic treatment in IBD.